Longevity small molecule
Metformin is an FDA-approved biguanide antidiabetic (marketed as Glucophage and generics) used as first-line therapy for Type 2 diabetes. It activates AMPK and is sometimes called the 'poor man's rapamycin' in longevity circles. The TAME (Targeting Aging with Metformin) trial is investigating whether metformin can delay age-related disease onset in non-diabetic adults. Observational data suggests reduced mortality in diabetics versus non-diabetic controls, but no randomized human lifespan trial has been completed.
Track clinical trial progress (TAME) and observational evidence. Do not publish dosing, sourcing, or treatment instructions. Separate observational associations from causal claims.
FDA-approved as Glucophage (metformin hydrochloride) as an adjunct to diet and exercise to improve glycemic control in adults and children with Type 2 diabetes mellitus.
Mechanism: activates AMPK (AMP-activated protein kinase), inhibits hepatic gluconeogenesis, and indirectly modulates mTOR — sometimes called 'poor man's rapamycin' in longevity discussions.
The TAME (Targeting Aging with Metformin) trial (NCT02432287), led by Nir Barzilai, is the first major clinical trial designed to test whether a drug can delay the onset of multiple age-related diseases in non-diabetic adults.
Observational data has reported lower mortality in metformin-treated diabetics versus matched non-diabetic controls (Bannister et al., 2014), but this is retrospective and subject to confounding — not proof of longevity benefit in non-diabetics.
No completed randomized controlled trial has demonstrated lifespan extension in humans. Multiple clinical reviews (e.g., Choi et al., 2021) note that metformin's geroprotective effect in non-diabetics remains unproven.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Cite the FDA label directly. Do not extend the diabetes approval to longevity claims.
Evidence level: Primary regulatory
Sources: ClinicalTrials.gov / U.S. National Library of Medicine, Cell Metabolism / Elsevier
TAME is registered on ClinicalTrials.gov (NCT02432287). It is ongoing — no lifespan or disease-delay results have been published. Update when results are available.
Evidence level: Peer reviewed
Sources: Diabetes, Obesity and Metabolism, Diabetes Research and Clinical Practice
These are retrospective observational studies, not randomized trials. State confounding limitations clearly. Do not present association as causation.
Evidence level: Community discussion
Sources: Aging and Disease / Metabolism reviews, Cell Metabolism / Elsevier
Frame as a hypothesis under active investigation, not as established anti-aging therapy. Clinical reviews emphasize that benefit in non-diabetics is unproven.
Source records are stored in the repo and linked from each claim.
FDA-approved prescribing label for Glucophage (metformin hydrochloride), indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
ClinicalTrials.gov registry entry for the TAME (Targeting Aging with Metformin) trial, a multi-center study investigating whether metformin can delay the onset of age-related diseases in non-diabetic adults.
Nir Barzilai and colleagues outline the scientific rationale and design of the TAME trial, arguing that metformin's AMPK-activating, insulin-sensitizing effects make it a candidate to target aging biology.
Observational retrospective cohort study (Bannister et al.) reporting that metformin-treated patients had lower mortality than matched non-diabetic controls, fueling interest in metformin as a longevity therapeutic.
Observational study reporting reduced mortality associated with metformin use in type 2 diabetes patients with heart failure, adding to the body of observational evidence.
Clinical review summarizing metformin's proposed mechanisms (AMPK activation, mTOR inhibition, insulin sensitization) and the evidence base for and against its use as a geroprotective agent.
5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enz...
Regulatory watchMethylene blue (methylthioninium chloride) is an FDA-approved medication (trade names Provayblue, Proveblue) for the tre...
Regulatory watchNAD+ (nicotinamide adenine dinucleotide) is an essential cellular coenzyme whose levels decline with age. Two precursors...
Regulatory watchRapamycin (sirolimus) is an FDA-approved mTOR inhibitor (marketed as Rapamune) used to prevent organ transplant rejectio...
Evidence review